Health giant Sonic Healthcare has forecast significant revenue from COVID-19 testing after these services helped a whopping full-year profit.
The company on Monday outlined that revenue from coronavirus testing played a notable part in a 149 per cent increase in net profit to $1.3 billion.
Sonic leaders said they expected significant coronavirus testing revenue to continue as the Delta variant spreads around the world.
Sonic workers are also injecting vaccines in the arms of many. The company is Australia's biggest non-government provider of COVID-19 vaccination.
Yet Sonic would not forecast earnings for this financial year, due to the unpredictability of the pandemic.
The company is evaluating takeover opportunities.
Shareholders will receive a final dividend of 55 cents per share, 65 per cent franked. This payment is higher than the previous final dividend of four cents per share, 30 per cent franked.
The performance was not enough for investors, who sent shares lower by 2.92 per cent to $41.58 at 1139 AEST.
